Page 81 - Genentech News Today

SEATTLE, November 02, 2023--ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced the addition of multiple industry veterans to its leadership team to support its growth.

Amy Pascal and Warner Bros. have won the rights to ‘How To Rule The World,’ which chronicles the research scandal and resignation of Stanford president Marc Tessier-Lavigne.

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023 Lausanne, Switzerland, November 02, 2023 – AC Immune...

Women experiencing menopause make up an ever-larger section of the workforce. But are employers responding to their needs?

Princeton is a national leader in campus sustainability. Meet the new electric fleet.

Discovery Education Offers New Resources for National STEM Day

Historic Collaborative Effort: Pharma Giants Rethink the Future of ...

BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé will retire in December, when he will be succeeded by Genentech CEO Alexander Hardy. The transition comes with BioMarin in the early stages of the commercial launch of Roctavian, the first FDA-approved hemophilia A gene therapy.

Amy Pascal and Warner Bros. have won the rights to ‘How To Rule The World,’ which chronicles the research scandal and resignation of Stanford president Marc Tessier-Lavigne.

PepGen (NASDAQ:PEPG – Get Free Report) and Affimed (NASDAQ:AFMD – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends. Insider and Institutional Ownership 71.8% of PepGen shares are […]